Loading…
Reported covered position: Senior Manager, American Society for Transplantation and Cellular Therapy
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications H.R. 2498, the PACT Act
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies H.R. 2498, the PACT Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTCT via SMITHBUCKLIN CORPORATION
2025 · second_quarter · Q2
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot - NIH Funding
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot Donor Leave Act The Accelerating Kids Access to Care Act Alleviating Barriers to Care Act
Source: Senate LDA
Appropriations, CAR-T Therapy clarification H.R. 2498, the PACT Act
Appropriations, CAR-T Therapy clarification H.R. 2498, the PACT Act
CMS coding and billing clarity for CAR-T therapies; CMS engagement on National Coverage Decision for CAR-T therapies H.R. 2498, the PACT Act
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications H.R. 2498, the PACT Act
- CMS coding and billing clarity for CAR-T therapies - CMS engagement on MS-DRG 018 for CAR-T therapies - Patient Care Episode - Financial Toxicity - Cancer Moonshot - The Accelerating Kids Access to Care Act - Alleviating Barriers to Care Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2025 · first_quarter · Q1
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot Donor Leave Act The Accelerating Kids Access to Care Act Alleviating Barriers to Care Act
- CMS coding and billing clarity for CAR-T therapies - CMS engagement on MS-DRG 018 for CAR-T therapies - Patient Care Episode - Financial Toxicity - Cancer Moonshot - The Accelerating Kids Access to Care Act - Alleviating Barriers to Care Act
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot - NIH Funding
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2024 · fourth_quarter · Q4
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot Donor Leave Act The Accelerating Kids Access to Care Act Alleviating Barriers to Care Act
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot - NIH Funding
- CMS coding and billing clarity for CAR-T therapies - CMS engagement on MS-DRG 018 for CAR-T therapies - Patient Care Episode - Financial Toxicity - Cancer Moonshot - The Accelerating Kids Access to Care Act - Alleviating Barriers to Care Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2024 · third_quarter · Q3
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot Donor Leave Act The Accelerating Kids Access to Care Act Alleviating Barriers to Care Act
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot - NIH Funding
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Patient Care Episode - Financial Toxicity - Cancer Moonshot - The Accelerating Kids Access to Care Act - Alleviating Barriers to Care Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2024 · second_quarter · Q2
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity Cancer Moonshot Donor Leave Act The Accelerating Kids Access to Care Act
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Covid funding - Patient Care Episode - Financial Toxicity - Cancer Moonshot - The Accelerating Kids Access to Care Act
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2024 · first_quarter · Q1
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Covid funding - Patient Care Episode - Financial Toxicity - Cancer Moonshot
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement - Cancer Moonshot
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity Cancer Moonshot
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2023 · fourth_quarter · Q4
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Covid funding - Patient Care Episode - Financial Toxicity
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2023 · third_quarter · Q3
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Covid funding - Patient Care Episode - Financial Toxicity
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2023 · second_quarter · Q2
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
- CMS coding and billing clarity for CAR-T therapies - CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies - Covid funding - Patient Care Episode - Financial Toxicity
- Appropriations - CAR-T Therapy clarification - Cures 2.0 Engagement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2023 · first_quarter · Q1
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies Covid funding, Patient Care Episode, Financial Toxicity
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2022 · fourth_quarter · Q4
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies Covid funding, Patient Care Episode, Financial Toxicity
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2022 · third_quarter · Q3
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies Covid funding, Patient Care Episode, Financial Toxicity
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2022 · second_quarter · Q2
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients Covid funding Patient-Care Episode Financial Toxicity
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies Covid funding, Patient Care Episode, Financial Toxicity
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2022 · first_quarter · Q1
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2021 · fourth_quarter · Q4
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2021 · third_quarter · Q3
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
ASTCT Appropriations Billing and Coding CAR-T Therapy Clarifications Cures 2.0 Engagement Revaccination of Immunosuppressed Patients
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2021 · second_quarter · Q2
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications, Cures 2.0 engagement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2021 · first_quarter · Q1
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
Appropriations, CAR-T Therapy clarification, Cures 2.0 Engagement
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications, Cures 2.0 engagement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · second_quarter · Q2
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies
Appropriations, CAR-T Therapy clarification
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · first_quarter · Q1
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
Appropriations, CAR-T Therapy clarification
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · fourth_quarter · Q4
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
Appropriations, CAR-T Therapy clarification
CMS coding and billing clarity for CAR-T therapies; CMS engagement and follow up on FY2021 new MS-DRG for CAR-T Therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · third_quarter · Q3
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
Appropriations, CAR-T Therapy clarification
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · second_quarter · Q2
Appropriations, CAR-T Therapy clarification
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2020 · first_quarter · Q1
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies
Appropriations, CAR-T Therapy clarification
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2019 · fourth_quarter · Q4
CMS coding and billing clarity for CAR-T therapies; CMS engagement on FY2021 new DRG for CAR-T Therapies H.R. 2498, the PACT Act
Appropriations, CAR-T Therapy clarification H.R. 2498, the PACT Act
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications H.R. 2498, the PACT Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2019 · third_quarter · Q3
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications H.R. 2498, the PACT Act
Appropriations, CAR-T Therapy clarification H.R. 2498, the PACT Act
CMS coding and billing clarity for CAR-T therapies; CMS engagement on National Coverage Decision for CAR-T therapies H.R. 2498, the PACT Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2019 · second_quarter · Q2
Appropriations, CAR-T Therapy clarification
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
CMS coding and billing clarity for CAR-T therapies; CMS engagement on National Coverage Decision for CAR-T therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2019 · first_quarter · Q1
Appropriations, CAR-T Therapy clarification
ASTCT appropriations; billing and coding; CAR-T Therapy clarifications
CMS coding and billing clarity for CAR-T therapies; CMS engagement on National Coverage Decision for CAR-T therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTCT via SMITHBUCKLIN CORPORATION
2019 · first_quarter · RR
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research
Healthcare, Medicare, CMS, hospital policy, insurance, education, research